Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MPX Marine Products Corp

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-2.05 (-2.53%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 607,830 shares is on pace to be much greater than NVS's 10-day average volume of 1,640,966 shares.


Gilead signs on for another oncology deal, this time with Jounce Therapeutics

9:23 am ET September 1, 2020 (MarketWatch)

Shares of Gilead Sciences Inc. (GILD) were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.'s (JNCE) tumor-infiltrating T regulatory cells program. Jounce, which said it plans to submit the antibody treatment to the Food and Drug Administration in the first half of next year, saw shares soar 91.7% in premarket trading on Tuesday. Gilead is paying $85 million upfront, making a $35 million investment if the deal closes, and allowing for up to $685 million in milestone payments. This is the latest in a handful of oncology deals ( that Gilead has engaged in 2020, including a $4.7 billion acquisition of Forty Seven Inc. and a $275 million stake in Pionyr Immunotherapeutics Inc. However, Gilead's stock has struggled to regain momentum ( from its year-to-date high in April, when it reported the first batch of clinical data for its experimental COVID-19 drug remdesivir. Gilead's stock is up 2.7% for the year, while the S&P 500 has gained 8.3% since the start of the year.

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

September 01, 2020 09:23 ET (13:23 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.